{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:18:35Z","timestamp":1792091915666,"version":"4.4.0"},"reference-count":49,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000771","name":"UK Charity Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","award":["RIA16-ST2-026"],"award-info":[{"award-number":["RIA16-ST2-026"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"UK Charity Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","award":["C16420\/A18066"],"award-info":[{"award-number":["C16420\/A18066"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"UK Charity Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","award":["PI19\/01007"],"award-info":[{"award-number":["PI19\/01007"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"UK Charity Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","award":["DTS21\/00130"],"award-info":[{"award-number":["DTS21\/00130"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BCI CRUK Centre","award":["RIA16-ST2-026"],"award-info":[{"award-number":["RIA16-ST2-026"]}]},{"name":"BCI CRUK Centre","award":["C16420\/A18066"],"award-info":[{"award-number":["C16420\/A18066"]}]},{"name":"BCI CRUK Centre","award":["PI19\/01007"],"award-info":[{"award-number":["PI19\/01007"]}]},{"name":"BCI CRUK Centre","award":["DTS21\/00130"],"award-info":[{"award-number":["DTS21\/00130"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["RIA16-ST2-026"],"award-info":[{"award-number":["RIA16-ST2-026"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["C16420\/A18066"],"award-info":[{"award-number":["C16420\/A18066"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PI19\/01007"],"award-info":[{"award-number":["PI19\/01007"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["DTS21\/00130"],"award-info":[{"award-number":["DTS21\/00130"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Oncolytic adenoviruses (OAd) can be employed to efficiently eliminate cancer cells through multiple mechanisms of action including cell lysis and immune activation. Our OAds, Ad\u0394\u0394 and Ad-3\u2206-A20T, selectively infect, replicate in, and kill adenocarcinoma cells with the added benefit of re-sensitising drug-resistant cells in preclinical models. Further modifications are required to enable systemic delivery in patients due to the rapid hepatic elimination and neutralisation by blood factors and antibodies. Here, we show data that support the use of coating OAds with gold nanoparticles (AuNPs) as a possible new method of virus modification to help augment tumour uptake. The pre-incubation of cationic AuNPs with Ad\u0394\u0394, Ad-3\u2206-A20T and wild type adenovirus (Ad5wt) was performed prior to infection of prostate\/pancreatic cancer cell lines (22Rv, PC3, Panc04.03, PT45) and a pancreatic stellate cell line (PS1). Levels of viral infection, replication and cell viability were quantified 24\u201372 h post-infection in the presence and absence of AuNPs. Viral spread was assessed in organotypic cultures. The presence of AuNPs significantly increased the uptake of Ad\u2206\u2206, Ad-3\u2206-A20T and Ad5wt in all the cell lines tested (ranging from 1.5-fold to 40-fold), compared to virus alone, with the greatest uptake observed in PS1, a usually adenovirus-resistant cell line. Pre-coating the Ad\u0394\u0394 and Ad-3\u2206-A20T with AuNPs also increased viral replication, leading to enhanced cell killing, with maximal effect in the most virus-insensitive cells (from 1.4-fold to 5-fold). To conclude, the electrostatic association of virus with cationic agents provides a new avenue to increase the dose in tumour lesions and potentially protect the virus from detrimental blood factor binding. Such an approach warrants further investigation for clinical translation.<\/jats:p>","DOI":"10.3390\/ijms23168884","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T09:42:56Z","timestamp":1660124576000},"page":"8884","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Complexing the Oncolytic Adenoviruses Ad\u2206\u2206 and Ad-3\u2206-A20T with Cationic Nanoparticles Enhances Viral Infection and Spread in Prostate and Pancreatic Cancer Models"],"prefix":"10.3390","volume":"23","author":[{"given":"Yang Kee Stella","family":"Man","sequence":"first","affiliation":[{"name":"Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"},{"name":"Centre for Sarcoma Molecular Pathology, Institute of Cancer Research (ICR), Sutton SM2 5NG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Aguirre-Hernandez","sequence":"additional","affiliation":[{"name":"Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"},{"name":"Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"},{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Martin-Duque","sequence":"additional","affiliation":[{"name":"Instituto Aragon\u00e9s de Ciencias de la Salud\/IIS Arag\u00f3n, 50009 Zaragoza, Spain"},{"name":"Fundaci\u00f3n Araid, 50018 Zaragoza, Spain"},{"name":"Departamento de Cirug\u00eda, Facultad de Medicina, Universidad de Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-6645","authenticated-orcid":false,"given":"Rebeca","family":"Gonz\u00e1lez-Pastor","sequence":"additional","affiliation":[{"name":"Instituto Aragon\u00e9s de Ciencias de la Salud\/IIS Arag\u00f3n, 50009 Zaragoza, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica (CENBIO), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito 170527, Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5680-2895","authenticated-orcid":false,"given":"Gunnel","family":"Halld\u00e9n","sequence":"additional","affiliation":[{"name":"Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rozengurt, E., and Eibl, G. (2021). Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. Cancers, 13.","DOI":"10.3390\/cancers13205126"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.ctrv.2022.102359","article-title":"PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence","volume":"104","author":"Bienkowski","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omto.2021.11.014","article-title":"Current development in adenoviral vectors for cancer immunotherapy","volume":"23","author":"Biegert","year":"2021","journal-title":"Mol. Oncolytics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omto.2021.02.007","article-title":"Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes","volume":"20","author":"Naseri","year":"2021","journal-title":"Mol. Oncolytics"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tripodi, L., Vitale, M., Cerullo, V., and Pastore, L. (2021). Oncolytic Adenoviruses for Cancer Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052517"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","article-title":"Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody","volume":"28","author":"Kanaya","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omto.2018.10.005","article-title":"Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus","volume":"11","author":"Havunen","year":"2018","journal-title":"Mol. Oncolytics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.ymthe.2021.05.015","article-title":"Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles","volume":"29","author":"Kakiuchi","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2014.02.034","article-title":"Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer","volume":"89","author":"Freytag","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/sj.mt.6300162","article-title":"Prostate cancer gene therapy clinical trials","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/09553000903419338","article-title":"Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer","volume":"86","author":"Liu","year":"2010","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_14","first-page":"34","article-title":"Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5\/3-CTV)","volume":"229","author":"Azab","year":"2014","journal-title":"J. Cell Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Laquente","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.gie.2020.02.012","article-title":"Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: A phase 1 trial","volume":"92","author":"Lee","year":"2020","journal-title":"Gastrointest. Endosc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.gt.3301398","article-title":"Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial","volume":"8","author":"Mulvihill","year":"2001","journal-title":"Gene Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","article-title":"Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes","volume":"108","author":"Parker","year":"2006","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-09-1960","article-title":"Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant (Ad\u2206\u2206) in prostate and pancreatic cancers","volume":"16","author":"Yanover","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/1078-0432.CCR-08-2008","article-title":"Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo","volume":"15","author":"Leitner","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/gt.2011.141","article-title":"The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models","volume":"18","author":"Cherubini","year":"2011","journal-title":"Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/hum.2012.046","article-title":"Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdDeltaDelta and Dietary Phytochemicals in Prostate Cancer Models","volume":"23","author":"Adam","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41389-017-0020-8","article-title":"Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad through Bcl-2-dependent attenuation of autophagy","volume":"7","author":"Millan","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ymthe.2004.03.017","article-title":"An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency","volume":"9","author":"Liu","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1089\/hum.2010.019","article-title":"Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts","volume":"21","author":"Radhakrishnan","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"15703","DOI":"10.18632\/oncotarget.7310","article-title":"The E1B19K-deleted oncolytic adenovirus mutant AdDelta19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11","volume":"7","author":"Pantelidou","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","article-title":"Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1","volume":"113","author":"Carlisle","year":"2009","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/1535-7163.MCT-17-0671","article-title":"The Novel Oncolytic Adenoviral Mutant Ad5-3Delta-A20T Retargeted to alphavbeta6 Integrins Efficiently Eliminates Pancreatic Cancer Cells","volume":"17","author":"Man","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1089\/hum.2011.218","article-title":"Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5","volume":"23","author":"Coughlan","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00259-021-05559-x","article-title":"PET\/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the \u201cCancer Integrin\u201d alphavbeta6 with Ga-68-Trivehexin","volume":"49","author":"Quigley","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/nbt887","article-title":"E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models","volume":"21","author":"Wang","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.1038\/s41598-019-49150-9","article-title":"Systemic delivery and SPECT\/CT in vivo imaging of (125)I-labelled oncolytic adenoviral mutants in models of pancreatic cancer","volume":"9","author":"Foster","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9536","DOI":"10.1016\/j.biomaterials.2011.08.069","article-title":"The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus","volume":"32","author":"Wang","year":"2011","journal-title":"Biomaterials"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1039\/C8RA09088B","article-title":"Gold nanoparticle coatings as efficient adenovirus carriers to non-infectable stem cells","volume":"9","author":"Hernandez","year":"2019","journal-title":"RSC Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.actbio.2021.07.047","article-title":"Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy","volume":"134","author":"Hernandez","year":"2021","journal-title":"Acta Biomater."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/path.5224","article-title":"Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma","volume":"248","author":"Neuzillet","year":"2019","journal-title":"J. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2009-12-260026","article-title":"Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors","volume":"116","author":"Alba","year":"2010","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/JVI.01878-08","article-title":"Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer","volume":"83","author":"Parker","year":"2009","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jgm.1008","article-title":"Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma","volume":"9","author":"Zheng","year":"2007","journal-title":"J. Gene Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jnci\/djt141","article-title":"A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy","volume":"105","author":"Ahmed","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omto.2018.12.003","article-title":"Enhanced Delivery of Oncolytic Adenovirus by Neural Stem Cells for Treatment of Metastatic Ovarian Cancer","volume":"12","author":"Mooney","year":"2019","journal-title":"Mol. Oncolytics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-11-20","article-title":"Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer","volume":"11","author":"Mader","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_45","first-page":"190","article-title":"Mesenchymal stem cell-mediated delivery of therapeutic adenoviral vectors to prostate cancer","volume":"10","author":"Muhammad","year":"2019","journal-title":"Stem Cell Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107592","DOI":"10.1016\/j.intimp.2021.107592","article-title":"Exosomal microRNA-98-5p from hypoxic bone marrow mesenchymal stem cells inhibits myocardial ischemia-reperfusion injury by reducing TLR4 and activating the PI3K\/Akt signaling pathway","volume":"101","author":"Zhang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/OV.S66010","article-title":"Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: Novel state-of-the-art technology","volume":"4","author":"Ramirez","year":"2015","journal-title":"Oncolytic Virother"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Pathak, Y.V. (2019). Surface Modification of Gold Nanoparticles for Targeted Drug Delivery. Surface Modification of Nanoparticles for Targeted Drug Delivery, Springer International Publishing.","DOI":"10.1007\/978-3-030-06115-9"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Weklak, D., Pembaur, D., Koukou, G., J\u00f6nsson, F., Hagedorn, C., and Kreppel, F. (2021). Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions. Viruses, 13.","DOI":"10.3390\/v13071300"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/8884\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:06:36Z","timestamp":1760141196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/8884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":49,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23168884"],"URL":"https:\/\/doi.org\/10.3390\/ijms23168884","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]}}}